

# well

HAN-GINS Indxx Healthcare Innovation UCITS ETF - Acc

Factsheet | Data as of 31 May 2019

## Investment Objective

HAN-GINS Indxx Healthcare Innovation UCITS ETF (WELL) is a UCITS compliant Exchange Traded Fund domiciled in Ireland. WELL tracks the Indxx Advanced Life Sciences & Smart Healthcare Thematic Index (Net Total Return), an index designed to measure the performance of performance of large, mid and small-capitalisation companies primarily listed on an exchange in Developed and Emerging Markets that are involved in the Advanced Life Sciences & Smart Healthcare sector.

## Why WELL?



### Transparent, Modern Approach:

WELL follows a transparent rules-based, free-float weighed index ensuring only investible companies are included within the ETF.



### Diversified:

In a single trade, WELL provides access to a basket of companies from Developed and Emerging markets with high exposure to the healthcare innovation theme.



### Unconstrained Approach:

WELL transcends traditional industry and sector classifications to provide exposure to an emerging theme.

## Key Risks

1. The value of equities and equity-related securities can be affected by daily stock and currency market movements.
2. Emerging & frontier markets are subject to greater market volatility than developed markets.
3. Investors' capital is fully at risk and investors may not get back the amount originally invested.
4. Exchange rate fluctuations could have a negative or positive effect on returns.

## ETF Advantages

Diversified	Liquid
Transparent	Cost-efficient
Tradable	

## Trading Information

Exchange	B'berg Code / Ticker	RIC	SEDOL	ISIN	CCY
London Stock Exchange	WELL LN	HAWELL.L	BJVBGL7	IE00BJQTJ848	USD
London Stock Exchange	WELP LN	WELP.L	BJVBGM8	IE00BJQTJ848	GBP
Borsa Italiana	WELL IM	WELL.MI	BHRWXD1	IE00BJQTJ848	EUR
Deutsche Boerse XETRA	W311.GY	W311.DE	BJ02354	DE000A2PE7K4	EUR

## Key Facts

Inception Date	04/04/2019
Index	Indxx Advanced Life Sciences & Smart Healthcare Healthcare Thematic Index
Number of Holdings	90
Base Currency	USD
Index PE Ratio	44.79
Index Dividend Yield (Est)	0.45%
Income Treatment	Accumulating
TER	75 bps
Rebalance Frequency	Annually, June
Fund Domicile	Ireland
Replication Style	Physical
Registered for Sale	IE, UK, IT, DE
Fund Reporting Status	Yes
UCITS Compliant	Yes
UK SIPP Eligibility	Yes
UK ISA Eligibility	Yes
Custodian & Administrator	BNY Mellon
Portfolio Manager	Vident Investment Advisory, LLC
Net Assets	1,169,322.29 (USD)
Net Assets of Share Class	1,169,322.29 (USD)
Shares Outstanding	160,000

## Contact

+44 (0)20 3794 1800  
info@HANetf.com

HANetf Ltd, City Tower, 40 Basinghall St,  
London, EC2V 5DE

# well

HAN-GINS Indxx Healthcare Innovation UCITS ETF - Acc

Factsheet | Data as of 31 May 2019

## Index Information

Indxx Advanced Life Sciences & Smart Healthcare Thematic Index (Net Total Return ) is managed according to a published, rules-based methodology. It is designed to measure the performance of an investable universe of publicly-traded companies that are involved in healthcare innovation. To be included, companies must derive revenue from themes including Robotics, Nanotechnology, Genome Sequencing, Healthcare Trackers, Biological Engineering , Bioinformatics, Neuroscience, Medical Devices For further information, visit [www.Indxx.com](http://www.Indxx.com)

## Index Performance and Volatility Indicators (USD)

Period	Return (%)	Volatility (%)
2015	12.72%	17.52%
2016	0.12%	17.58%
2017	34.28%	9.92%
2018	6.62%	19.20%
2019*	6.16%	17.10%


\*Index data up to the 28/02/2019. Fund data from 04/04/2019

Performance before inception is based on back tested data. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of that strategy would have been. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. Past performance for the index is in USD and shown net of fees. Past performance and back tested index performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. It is provided for illustrative purposes only. Indices cannot be invested in directly. Investors should read the prospectus of the Issuer ("Prospectus") before investing and should refer to the section of the Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product. Source HANetf /Indxx.

## Top 10 Index Holdings (%)

Company	(%)	Company	(%)
Boston Scientific Corp	5.41%	Zimmer Biomet Holdings Inc	4.03%
Edwards Lifesciences Corp	5.40%	Regeneron Pharmaceuticals Inc	3.98%
Illumina Inc	5.06%	Agilent Technologies Inc	3.72%
Medtronic PLC	4.98%	Align Technology Inc	3.60%
Intuitive Surgical Inc	4.47%	Biogen Inc	3.48%

## Regional Exposure



- United States 65.94%
- Other 9.87%
- Ireland 6.91%
- Japan 6.49%
- China 6.37%
- United Kingdom 4.42%

## Sub-Theme Breakdown

Sector	Weight (%)
Medical Devices	47.54%
Biological engineering	29.10%
Neuroscience	9.67%
Genome sequencing	5.74%
Robotics	4.51%
Healthcare tracker	2.40%
Bioinformatics	0.97%
Nanotechnology	0.06%

## ETF Partner

HAN-GINS Indxx Healthcare Innovation UCITS ETF has been developed by HANetf and Gins Global Investment Management, a multi-billion dollar asset management company founded in 2000 with operations in North America, Africa, Middle East and Asia-Pacific. [www.ginsglobal.com](http://www.ginsglobal.com)



## About HANetf

HANetf is an independent provider of UCITS ETFs, working with asset management companies to bring differentiated, modern and innovative exposures to European ETF investors. Via our white-label ETF platform, HANetf provides a complete operational, regulatory, distribution and marketing solution for asset managers to launch and manage UCITS ETFs.

## Contact

+44 (0)20 3794 1800  
[info@HANetf.com](mailto:info@HANetf.com)

HANetf Ltd, City Tower, 40 Basinghall St,  
 London, EC2V 5DE

HAN-etf @HANetf  
[www.hanetf.com](http://www.hanetf.com)

**IMPORTANT INFORMATION**

This factsheet is approved for professional use only. The fund to which it relates is a UCITS fund and accordingly is available for purchase by all investor types, including retail and professional investors. The content in this document is issued by HANetf Limited ("HANetf"), an appointed representative of Mirabella Advisers LLP, which is authorised and regulated by the Financial Conduct Authority ("FCA"). For professional clients only. Past performance is not a reliable indicator of future performance. Any historical performance included on this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided on this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements.

Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice. These products may not be available in your market or suitable for you. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment. An investment in an ETF is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETFs involve numerous risks including among others, general market risks relating to the relevant underlying index, exchange rate risks, interest rate risks, inflationary risks, liquidity risks and legal and regulatory risks.

The information contained on this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the Issuers or their products are authorised or registered for distribution and where no prospectus of any of the Issuers has been filed with any securities commission or regulatory authority. No document or information on this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the Issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes. The products discussed on this document are issued by HANetf ICAV.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. Therefore, readers are cautioned not to place undue reliance on these forward-looking statements. HANetf ICAV is an open-ended Irish collective asset management vehicle which is constituted as an umbrella fund with segregated liability between sub-funds and with variable capital organised under the laws of Ireland and authorised by the Central Bank of Ireland ("CBI"). Investors should read the prospectus of HANetf ICAV ("HANetf Prospectus") before investing and should refer to the section of the HANetf Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the Shares.

**RISK FACTORS**

While the general risk factors set out in the section entitled Risk Factors in the Prospectus apply to the SubFund, the following risk factors described in the Prospectus under the headings Absence of prior active market, Capital Controls and Sanctions Risk, Concentration Risk, Emerging Market Risks, Currency Risk, Interest Rate Risk, Liquidity of Investments, Small- and Mid-Capitalisation Risk, Political and/or Legal/Regulatory Risk, Regulatory Restrictions, Index Rebalancing and Costs Risk and Issuer-specific Risk are particularly relevant for the Sub-Fund. In addition, the following to the above, the following risk is also relevant to this Sub-Fund: 9.1 Sectoral Investment Risk To the extent the SubFund invests a significant portion of its assets in the securities of companies of a sector, it is more likely to be impacted by events or conditions affecting that sector. The Sub-Fund may invest a relatively large percentage of its assets in sectors, including the consumer discretionary sector, the information technology sector and the financial sector, which sectors have tended to form a relatively large percentage of the Index. Further details of the specific risk relevant to these sectors are set out below.

**Consumer Discretionary Sector Risk:**

This sector consists of, for example, automobile, media and retail companies. The consumer discretionary sector of the economy can be significantly affected by, among other things, economic growth, worldwide demand and consumers' disposable income levels and propensity to spend.

**Information Technology Sector Risk:**

This sector can be significantly affected by, among other things, the supply and demand for specific products and services, the pace of technological development and government regulation. Challenges facing companies in the information technology sector include distressed cash flows due to the need to commit substantial capital to meet increasing competition, particularly in formulating new products and services using new technology, technological innovations that make existing products and services obsolete, and satisfying consumer demand.

**Contact**